PreSERVE-AMI

Autor: Marc Klapholz, Pamela Hyde, Timothy D. Henry, Ahmed Abdel-Latif, Douglas W. Losordo, Dean J. Kereiakes, Vitaly Druker, David M. Shavelle, Charles J. Davidson, Gregory W. Barsness, David J. Mazzo, Thomas J. Moss, Candice Junge, Catalin Toma, Andrew L. Pecora, Arshed A. Quyyumi, Robert A. Preti, Stephen Frohwein, Nabil Dib, Richard A. Schatz, Robin L. Smith, Martin Cohen, Alejandro Vasquez, Anna Maria Kanakaraj, Gary L. Schaer, Amy S. Chung, Joseph Poole
Rok vydání: 2017
Předmět:
Zdroj: Circulation Research. 120:324-331
ISSN: 1524-4571
0009-7330
0149-5364
DOI: 10.1161/circresaha.115.308165
Popis: Rationale: Despite direct immediate intervention and therapy, ST-segment–elevation myocardial infarction (STEMI) victims remain at risk for infarct expansion, heart failure, reinfarction, repeat revascularization, and death. Objective: To evaluate the safety and bioactivity of autologous CD34+ cell (CLBS10) intracoronary infusion in patients with left ventricular dysfunction post STEMI. Methods and Results: Patients who underwent successful stenting for STEMI and had left ventricular dysfunction (ejection fraction≤48%) ≥4 days poststent were eligible for enrollment. Subjects (N=161) underwent mini bone marrow harvest and were randomized 1:1 to receive (1) autologous CD34+ cells (minimum 10 mol/L±20% cells; N=78) or (2) diluent alone (N=83), via intracoronary infusion. The primary safety end point was adverse events, serious adverse events, and major adverse cardiac event. The primary efficacy end point was change in resting myocardial perfusion over 6 months. No differences in myocardial perfusion or adverse events were observed between the control and treatment groups, although increased perfusion was observed within each group from baseline to 6 months ( P P =0.05). At 1 year, 3.6% (N=3) and 0% deaths were observed in the control and treatment group, respectively. Conclusions: This PreSERVE-AMI (Phase 2, randomized, double-blind, placebo-controlled trial) represents the largest study of cell-based therapy for STEMI completed in the United States and provides evidence supporting safety and potential efficacy in patients with left ventricular dysfunction post STEMI who are at risk for death and major morbidity. Clinical Trial Registration: URL: http://www.clinicaltrials.gov . Unique identifier: NCT01495364.
Databáze: OpenAIRE
Externí odkaz: